Haemophilia A Treatment Rationale

• Pathophysiology: Haemophilia A is a genetic disorder characterized by a deficiency in clotting factor VIII. This deficiency impairs the blood clotting process, leading to prolonged bleeding.
• Treatment Goal: The primary goal is to replace the deficient clotting factor VIII to restore normal haemostasis and prevent or manage bleeding episodes.
• Option Analysis:
  • Epoprostenol: Used for pulmonary hypertension. Not relevant for Haemophilia A.
  • Oral corticosteroids: Used for inflammation or immune conditions. Not a primary treatment for Haemophilia A.
  • Recombinant factor VIII concentrate: This is a synthetic replacement therapy that directly addresses the factor VIII deficiency. It is the standard and preferred treatment for Haemophilia A.
  • Blood transfusion: A general measure for severe blood loss, but not specific or ideal for correcting the underlying clotting factor deficiency in Haemophilia A.
• Conclusion: Replacing the missing factor is the most direct and effective treatment. Recombinant factor VIII concentrate provides this replacement therapy.

Therefore, the treatment of choice for Haemophilia A is Recombinant factor VIII concentrate.